Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2024-10-09 DOI:10.1016/j.ygyno.2024.07.019

Linda Duska , Yang Xiang , Kosei Hasegawa , Giovanni Scambia , Manuel Leiva , Pier Anyelo Elias , Alejandro Acevedo , Julia Vizkeleti , Andrea Juliana Gomes , Fernando Contreras Mejía , Ari Reiss , Ali Ayhan , Jung-Yun Lee , Valeriya Saevets , Flora Zagouri , Kan Li , Karin Yamada , Sarper Toker , Sandro Pignata , Domenica Lorusso

引用次数: 0

查看原文本刊更多论文

Pembrolizumab 联合化放疗治疗高风险局部晚期宫颈癌：随机、双盲、III 期 ENGOT-cx11/GOG-3047/KEYNOTE-A18 研究

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy